Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on November 27, 2020, for the month of November 2020. The document serves as a notification regarding the provisional dividend dates for the fiscal year 2021.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The content is exclusively focused on corporate governance and shareholder communication regarding dividend schedules.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces the indicative dates for dividend payments for the four quarters of 2021.
Guidance, Outlook, and Management Commentary
Management has provided a schedule of indicative dates for the 2021 dividend cycle. The filing explicitly states that these dates are provisional and may be subject to change. No forward-looking financial guidance or risk factors are included in this specific report.
| Quarter | Announcement Date | Ex-Dividend Date | Record Date | Payable Date |
|---|---|---|---|---|
| Q1 2021 | April 28, 2021 | May 20, 2021 | May 21, 2021 | July 8, 2021 |
| Q2 2021 | July 28, 2021 | August 19, 2021 | August 20, 2021 | October 7, 2021 |
| Q3 2021 | October 27, 2021 | November 18, 2021 | November 19, 2021 | January 13, 2022 |
| Q4 2021 (Final) | February 9, 2022 | February 24, 2022 | February 25, 2022 | April 7, 2022 |
Important Facts for Investors to Verify
- The dividend dates listed are indicative and subject to change.
- This filing does not contain financial results; investors should refer to the company's Form 20-F or quarterly earnings releases for performance data.
- The filing confirms the company's intent to maintain its dividend schedule for 2021, pending final board approval.